Targeting histone deacetylase 6 mediates a dual anti‐melanoma effect: Enhanced antitumor immunity and impaired cell proliferation

[1]  D. Woods,et al.  A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs , 2014, The Journal of Immunology.

[2]  C. Thompson.  Belinostat approved for use in treating rare lymphoma. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[3]  R. Madan,et al.  Nivolumab: promising survival signal coupled with limited toxicity raises expectations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Atadja,et al.  The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity , 2013, Melanoma research.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  A. Kozikowski,et al.  Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. , 2012, Journal of medicinal chemistry.

[7]  Jiuhong Kang,et al.  Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. , 2012, DNA and cell biology.

[8]  S. Milstien,et al.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy , 2012, Oncogene.

[9]  E. Seto,et al.  Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer , 2012, Immunology and cell biology.

[10]  H. Weir,et al.  Melanoma surveillance in the United States: overview of methods. , 2011, Journal of the American Academy of Dermatology.

[11]  Kyle V. Butler,et al.  Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells , 2011, Molecular and Cellular Biology.

[12]  A. Younes,et al.  HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. , 2011, Blood.

[13]  S. Bae,et al.  Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. , 2011, American journal of translational research.

[14]  D. Rigel,et al.  Epidemiology of melanoma. , 2010, Seminars in cutaneous medicine and surgery.

[15]  F. Marincola,et al.  Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. , 2009, Cancer research.

[16]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[18]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[19]  A. Kozikowski,et al.  Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. , 2008, Journal of medicinal chemistry.

[20]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[21]  R. Johnstone,et al.  Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents , 2007, Expert review of anticancer therapy.

[22]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[23]  Hanlee P. Ji,et al.  Multiplexed protein detection by proximity ligation for cancer biomarker validation , 2007, Nature Methods.

[24]  E. Olson,et al.  Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10 , 2006, Cell.

[25]  T. Tomasi,et al.  Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. , 2005, International immunology.

[26]  F. Sánchez‐Madrid,et al.  HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. , 2004, Immunity.

[27]  P. Atadja,et al.  Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824 , 2004, Cancer Research.

[28]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[29]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[30]  T. Muley,et al.  Cytokine secretion: clinical relevance of immunosuppression in non-small cell lung cancer. , 2001, Lung cancer.

[31]  F. Garrido,et al.  Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.

[32]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[33]  T. Tomasi,et al.  Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors1 , 2000, The Journal of Immunology.

[34]  Y. Yun,et al.  Effects of tetrandrine and fangchinoline on human platelet aggregation and thromboxane B2 formation. , 1999, Journal of ethnopharmacology.

[35]  S. Meng,et al.  p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells , 1998 .

[36]  V. Pang,et al.  Regression of established mouse leukemia by GM-CSF-transduced tumor vaccine: implications for cytotoxic T lymphocyte responses and tumor burdens. , 1997, Human gene therapy.

[37]  D. Ruiter,et al.  MHC antigens in human melanomas. , 1991, Seminars in cancer biology.

[38]  A. Daar,et al.  The membrane antigens of human colorectal cancer cells: demonstration with monoclonal antibodies of heterogeneity within and between tumours and of anomalous expression of HLA-DR. , 1983, European journal of cancer & clinical oncology.

[39]  D. Buglio,et al.  Hodgkin lymphoma HDAC11 plays an essential role in regulating OX40 ligand expression in , 2013 .

[40]  T. Tomasi,et al.  Histone deacetylase regulation of immune gene expression in tumor cells , 2008, Immunologic research.

[41]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[42]  Ronald Breslow,et al.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.

[43]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[44]  S. Meng,et al.  WAF 1 is required for butyrate-mediated growth inhibition of human colon cancer cells , 1998 .

[45]  T. Iijima,et al.  Expression of MHC class II antigens in human lung cancer cells , 1991, Virchows Archiv. B, Cell pathology including molecular pathology.

[46]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.